- Home
- IBRX vs MNR Comparison
IBRX vs MNR Comparison
Compare IBRX & MNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- MNR
- Stock Information
- Founded
- IBRX 2014
- MNR 2017
- Country
- IBRX United States
- MNR United States
- Employees
- IBRX N/A
- MNR N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- MNR
- Sector
- IBRX Health Care
- MNR
- Exchange
- IBRX Nasdaq
- MNR Nasdaq
- Market Cap
- IBRX 2.3B
- MNR 2.0B
- IPO Year
- IBRX N/A
- MNR 2023
- Fundamental
- Price
- IBRX $2.58
- MNR $12.30
- Analyst Decision
- IBRX Strong Buy
- MNR Strong Buy
- Analyst Count
- IBRX 6
- MNR 4
- Target Price
- IBRX $9.83
- MNR $21.00
- AVG Volume (30 Days)
- IBRX 9.7M
- MNR 310.6K
- Earning Date
- IBRX 11-10-2025
- MNR 11-07-2025
- Dividend Yield
- IBRX N/A
- MNR 22.36%
- EPS Growth
- IBRX N/A
- MNR N/A
- EPS
- IBRX N/A
- MNR 1.95
- Revenue
- IBRX $56,600,000.00
- MNR $930,939,000.00
- Revenue This Year
- IBRX $629.94
- MNR $20.49
- Revenue Next Year
- IBRX $109.91
- MNR $34.68
- P/E Ratio
- IBRX N/A
- MNR $6.32
- Revenue Growth
- IBRX 4227.22
- MNR 11.58
- 52 Week Low
- IBRX $1.83
- MNR $11.79
- 52 Week High
- IBRX $6.82
- MNR $19.00
- Technical
- Relative Strength Index (RSI)
- IBRX 54.54
- MNR 41.07
- Support Level
- IBRX $2.30
- MNR $11.90
- Resistance Level
- IBRX $2.67
- MNR $13.01
- Average True Range (ATR)
- IBRX 0.12
- MNR 0.36
- MACD
- IBRX 0.01
- MNR 0.05
- Stochastic Oscillator
- IBRX 75.68
- MNR 33.12
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About MNR Mach Natural Resources LP
Mach Natural Resources LP is an independent upstream oil and gas company. The company is focused on the acquisition, development and production of oil, natural gas, and NGL reserves in the Anadarko Basin region of Western Oklahoma, Southern Kansas, and the panhandle of Texas.